RefDoc
Haut

Faire une nouvelle recherche
Make a new search
Lancer la recherche


Titre du document / Document title

Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis

Auteur(s) / Author(s)

SALVO Virgilo A. (1 2) ; BOUE Stephen M. (3) ; FONSECA Juan P. (1 2) ; ELLIOTT Steven (1 4) ; CORBITT Cynthia (5) ; COLLINS-BUROW Bridgette M. (1) ; CURIEL Tyler J. (1 2) ; SRIVASTAV Sudesh K. (2 6) ; SHIH Betty Y. (3) ; CARTER-WIENTJES Carol (3) ; WOOD Charles E. (7) ; ERHARDT Paulw. (8) ; BECKMAN Barbara S. (2 4 9) ; MCLACHLAN John A. (2 4 9) ; CLEVELAND Thomas E. (3) ; BUROW Matthew E. (1 2 4 9 10) ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

(1) Section of Hematology and Medical Oncology, Department of Medicine, Tulane University Health Science Center, ETATS-UNIS
(2) The Tulane Cancer Center, Tulane University Health Science Center, ETATS-UNIS
(3) Southern Regional Research Center, U.S. Department of Agriculture, New Orleans, Los Angeles, ETATS-UNIS
(4) The Center for Bioenvironmental Research, Tulane University Health Science Center, ETATS-UNIS
(5) Department of Biology, University of Louisville, Louisville, Kentucky, ETATS-UNIS
(6) Department of Biostatistics, Tulane University Health Science Center, ETATS-UNIS
(7) Department of Pathology/Section on Comparative Medicine,Wake Forest University School of Medicine, Winston -Salem, North Carolina, ETATS-UNIS
(8) Center for Drug Design and Development, University of Toledo, Toledo, Ohio, ETATS-UNIS
(9) Department of Pharmacology, Tulane University Health Science Center, ETATS-UNIS
(10) Department of Surgery, Tulane University Health Science Center, ETATS-UNIS

Résumé / Abstract

Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II, and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (-53.4%) and BG-1 cells (-73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.

Revue / Journal Title

Clinical cancer research    ISSN  1078-0432   CODEN CCREF4 

Source / Source

2006, vol. 12, no23, pp. 7159-7164 [6 page(s) (article)] (30 ref.)

Langue / Language

Anglais

Editeur / Publisher

American Association for Cancer Research, Philadelphia, PA, ETATS-UNIS  (1995) (Revue)

Mots-clés anglais / English Keywords

Ovarian diseases

;

Female genital diseases

;

Mammary gland diseases

;

Malignant tumor

;

Ovary carcinoma

;

Breast cancer

;

Tumorigenicity

;

Carcinogenesis

;

Ovary cancer

;

Breast carcinoma

;

Human

;

Antiestrogen

;

Mots-clés français / French Keywords

Ovaire pathologie

;

Appareil génital femelle pathologie

;

Glande mammaire pathologie

;

Tumeur maligne

;

Carcinome ovaire

;

Cancer du sein

;

Tumorigénicité

;

Carcinogenèse

;

Cancer ovaire

;

Carcinome sein

;

Homme

;

Antioestrogène

;

Mots-clés espagnols / Spanish Keywords

Ovario patología

;

Aparato genital hembra patología

;

Glándula mamaria patología

;

Tumor maligno

;

Carcinoma ovario

;

Cáncer de pecho

;

Tumorigenicidad

;

Carcinogénesis

;

Cáncer del ovario

;

Carcinoma pecho

;

Hombre

;

Antiestrógeno

;

Localisation / Location

INIST-CNRS, Cote INIST : 26073, 35400014510391.0410

Nº notice refdoc (ud4) : 18353411



Faire une nouvelle recherche
Make a new search
Lancer la recherche
Bas